Download PDF
Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2024; 20: s00441790566
DOI: 10.1055/s-0044-1790566
Review Article
Clinical Oncology

Gastric Cancer: Molecular Characterization, Therapeutic Innovations, and Perspectives

Authors

  • Emily Tonin da Costa 

    1   Department Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

  • Sergio Jobim de Azevedo 

    1   Department Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
    2   Seção de Oncologia Clínica, OC Oncoclínicas Moinhos de Vento, Porto Alegre, RS, Brazil

  • Alexandre A. Jácome 

    3   Seção de Oncologia Clínica, Cancer Center Oncoclínicas, Belo Horizonte, MG, Brazil

Funding The authors declare that they did not receive funding from agencies in the public, private or non-profit sectors to conduct the present study. Clinical Trials None.
Further Information
  Permissions and Reprints All articles of this category
Preview

Abstract

Introduction Gastric cancer is the fifth most common neoplasm and the fourth leading cause of cancer-related death in the world. The present review aims to offer to the oncologic community the molecular characterization of gastric cancer, the therapeutic innovations and the perspectives for the systemic therapy for gastric cancer.

Materials and Methods We searched for articles in the PubMed database using Medical Subject Headings (MeSH). The latest publications and proceedings of meetings were also reviewed.

Results The cornerstone of the systemic therapy for gastric cancer is the dual combination of fluoropyrimidines and platin-based chemotherapy. Nevertheless, it is recommended that gastric cancer patients are tested for human epidermal growth factor receptor 2 (HER2), high-frequency microsatellite instability (MSI-H), programmed cell death-ligand 1(PD-L1), and claudin 18.2 expression. If HER2-positive, trastuzumab plus pembrolizumab should be added to the doublet chemotherapy. Anti-programmed cell death-1 (anti-PD-1) therapy, such as nivolumab or pembrolizumab, should also be added to chemotherapy in MSI-H and in the PD-L1-positive patients. Patients who present overexpression of claudin 18.2 should be treated with the combination of zolbetuximab and oxaliplatin-based chemotherapy. Immunotherapy may also be considered in patients with high tumor mutational burden. Clinical trials evaluating fibroblast growth factor receptor 2 (FGFR2) inhibitors and the dual inhibition anti-PD-1 and anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (anti-TIGIT) are promising.

Conclusions The clinical applicability of precision medicine in gastric cancer has risen in the past few decades, leading to substantial improvements in the efficacy of the systemic therapy. Testing patients for biomarkers is paramount for the appropriate management of advanced disease. Ongoing clinical trials evaluating new therapeutic strategies are promising and offer optimism for the patients affected by this challenging disease.

Keywords

stomach neoplasms - antineoplastic agents - precision medicine

Author's Contributions

ETC, SJA, and AAJ: collection and assembly of data, conception and design, data analysis and interpretation, final approval of the manuscript, manuscript writing, and provision of study materials or patient.




Publication History

Received: 08 March 2024

Accepted: 27 June 2024

Article published online:
16 December 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Emily Tonin da Costa, Sergio Jobim de Azevedo, Alexandre A. Jácome. Gastric Cancer: Molecular Characterization, Therapeutic Innovations, and Perspectives. Brazilian Journal of Oncology 2024; 20: s00441790566.
DOI: 10.1055/s-0044-1790566
 

  • References

  • 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (03) 229-263
    Search in Google Scholar
  • 2 de Oliveira Santos M, de Lima FCdS, Martins LFL, Oliveira JFP, de Almeida LM, de Camargo Cancela M. Estimativa de incidência de câncer no Brasil, 2023–2025. Rev Bras Cancerol 2023 ;69(1)
    Search in Google Scholar
  • 3 Lordick F, Carneiro F, Cascinu S. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (10) 1005-1020
    Search in Google Scholar
  • 4 Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72 (01) 37-41
    Search in Google Scholar
  • 5 Moehler M, Eimermacher A, Siebler J. et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92 (12) 2122-2128
    Search in Google Scholar
  • 6 Network CGAR. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513 (7517) 202-209
    Search in Google Scholar
  • 7 Bang Y-J, Van Cutsem E, Feyereislova A. et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742) 687-697
    Search in Google Scholar
  • 8 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398 (10294): 27-40
    Search in Google Scholar
  • 9 Rha SY, Oh DY, Yañez P. et al; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24 (11) 1181-1195
    Search in Google Scholar
  • 10 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38 (01) 1-10
    Search in Google Scholar
  • 11 Doki Y, Ajani JA, Kato K. et al; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022; 386 (05) 449-462
    Search in Google Scholar
  • 12 Shah MA, Kennedy EB, Alarcon-Rozas AE. et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol 2023; 41 (07) 1470-1491
    Search in Google Scholar
  • 13 Shitara K, Van Cutsem E, Bang Y-J. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020; 6 (10) 1571-1580
    Search in Google Scholar
  • 14 Janjigian YY, Kawazoe A, Yañez P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021; 600 (7890) 727-730
    Search in Google Scholar
  • 15 Shitara K, Bang YJ, Iwasa S. et al; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 2020; 382 (25) 2419-2430
    Search in Google Scholar
  • 16 Van Cutsem E, di Bartolomeo M, Smyth E. et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 2023; 24 (07) 744-756
    Search in Google Scholar
  • 17 Meric-Bernstam F, Hamilton EP, Beeram M. et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. J Clin Oncol 2021; 39 (3, suppl) 164
    Search in Google Scholar
  • 18 Elimova E, Ajani JA, Burris III HA. et al. Zanidatamab+ chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). American Society of Clinical Oncology; 2023
    Search in Google Scholar
  • 19 Shitara K, Lordick F, Bang Y-J. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023; 401 (10389): 1655-1668
    Search in Google Scholar
  • 20 Shah MA, Shitara K, Ajani JA. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023; 29 (08) 2133-2141
    Search in Google Scholar
  • 21 Lieto E, Ferraraccio F, Orditura M. et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15 (01) 69-79
    Search in Google Scholar
  • 22 Ohtsu A, Shah MA, Van Cutsem E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29 (30) 3968-3976
    Search in Google Scholar
  • 23 Fuchs CS, Tomasek J, Yong CJ. et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383 (9911) 31-39
    Search in Google Scholar
  • 24 Wilke H, Muro K, Van Cutsem E. et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15 (11) 1224-1235
    Search in Google Scholar
  • 25 Lorenzen S, Thuss-Patience P, Pauligk C. et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 2022; 165: 48-57
    Search in Google Scholar
  • 26 Pavlakis N, Shitara K, Sjoquist KM. et al. INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). American Society of Clinical Oncology; 2023
    Search in Google Scholar
  • 27 Wainberg ZA, Enzinger PC, Kang Y-K. et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2022; 23 (11) 1430-1440
    Search in Google Scholar
  • 28 Shah MA, Cho J-Y, Tan IB. et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction. Oncologist 2016; 21 (09) 1085-1090
    Search in Google Scholar
  • 29 Iveson T, Donehower RC, Davidenko I. et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014; 15 (09) 1007-1018
    Search in Google Scholar
  • 30 Malka D, François E, Penault-Llorca F. et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019; 115: 97-106
    Search in Google Scholar
  • 31 Catenacci DVT, Tebbutt NC, Davidenko I. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18 (11) 1467-1482
    Search in Google Scholar
  • 32 Klempner SJ, Shitara K, Sison A. et al. STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. American Society of Clinical Oncology; 2023
    Search in Google Scholar
  • 33 Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer 2022; 22 (04) 273-305
    Search in Google Scholar
  • 34 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378 (08) 731-739
    Search in Google Scholar
  • 35 Doebele RC, Drilon A, Paz-Ares L. et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21 (02) 271-282
    Search in Google Scholar
  • 36 Kang JH, Lee SI, Lim DH. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30 (13) 1513-1518 Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035
    Search in Google Scholar
  • 37 Shitara K, Doi T, Dvorkin M. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (11) 1437-1448
    Search in Google Scholar
  • 38 Janjigian YY. et al. “Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.”. Lancet (London, England) vol. 402,10418 (2023): 2197-2208
  • 39 Tabernero J. et al. “HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.”. Future oncology (London, England) vol. 18,29 (2022): 3255-3266
  • 40 Janjigian YY. et al. EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. JCO 41, 433248-433248(2023).